NeoGenomics is trading 5.5% down at $13.13 as investors reposition ahead of its Q2 2026 earnings report scheduled for July 28, 2026.
- The stock has shown weakness in recent sessions despite a broadly positive healthcare sector, suggesting cautious sentiment regarding upcoming results and guidance.
- Market caution follows a series of mixed quarterly reports and the company's ongoing loss-making profile.